<DOC>
	<DOCNO>NCT00405704</DOCNO>
	<brief_summary>In 2-year , multisite , randomize , placebo-controlled trial involve 607 child vesicoureteral reflux diagnose first second febrile symptomatic urinary tract infecton , evaluate efficacy Trimethoprim-Sulfamethoxazole ( TMP-SMZ ) prophylaxis prevent recurrence ( primary outcome ) . Secondary outcome renal scarring , treatment failure ( composite recurrence scar ) , antimicrobial resistance .</brief_summary>
	<brief_title>Randomized Intervention Children With Vesicoureteral Reflux ( RIVUR )</brief_title>
	<detailed_description>This multicenter , randomize , double-blind , placebo-controlled trial design determine whether daily antimicrobial prophylaxis superior placebo prevent recurrence urinary tract infection ( UTI ) child vesicoureteral reflux ( VUR ) . Eligibility criterion describe elsewhere . Patients randomly assign treatment 2 year daily antimicrobial prophylaxis ( trimethoprim-sulfamethoxazole ) placebo . The study design recruit 600 child ( approximately 300 treatment group ) . The protocol encourage prompt evaluation child UTI symptom early therapy culture-proven UTIs . It expect approximately 10 % child discontinue study medication due allergic reaction . Assuming 20 % placebo event rate 10 % non-compliance rate , study 83 % power detect absolute 10 % event rate antimicrobial prophylaxis group . If placebo event rate instead 25 % , power 97 % detect absolute 10 % event rate treat group , even non-compliance high 15 % . The primary analysis intention-to-treat miss outcome data analyze UTI . In addition collect follow-up data urinary tract infection , renal scar antimicrobial resistance , quality life , compliance , safety parameter , utilization health resource , change VUR assess periodically throughout study .</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Urinary Tract Infections</mesh_term>
	<mesh_term>Vesico-Ureteral Reflux</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<mesh_term>Trimethoprim , Sulfamethoxazole Drug Combination</mesh_term>
	<criteria>Age randomization : least 2 month , less 6 year age . Note child young 1 month screen study . Diagnosed first second febrile symptomatic UTI within 112 day prior randomization Presence Grade I IV VUR base radiographic void cystourethrogram ( VCUG ) perform within 112 day diagnosis index UTI . Appropriately treated index febrile symptomatic UTI Index UTI diagnosis 112 day prior randomization History two UTIs prior randomization For patient le 6 month age randomization , gestational age le 34 week Comorbid urologic anomaly Hydronephrosis , SFU Grade 4 Ureterocele Urethral valve Solitary kidney Profoundly decrease renal size unilaterally ultrasound ( base 2 standard deviation mean age length ) perform within 112 day diagnosis index UTI Multicystic dysplastic kidney Neurogenic bladder Pelvic kidney fuse kidney Known sulfa allergy , inadequate renal hepatic function , Glucose6phosphate dehydrogenase deficiency condition contraindication use TMPSMZ History renal injury/disease Unable complete study protocol Congenital acquire immunodeficiency Underlying anomaly chronic disease could potentially interfere response therapy chronic gastrointestinal condition ( i.e. , malabsorption , inflammatory bowel disease ) , liver kidney failure , malignancy . Complex cardiac disease define Manual Procedures . Any known syndrome associate VUR bladder dysfunction Index UTI successfully treat Unlikely complete followup Family history anaphylactic reaction sulfa medication</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>71 Months</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Vesicoureteral Reflux</keyword>
	<keyword>Urinary Tract Infections</keyword>
	<keyword>Renal Scarring</keyword>
	<keyword>Antibiotic Resistance</keyword>
	<keyword>Controlled Clinical Trial</keyword>
	<keyword>Trimethoprim-Sulfamethoxazole</keyword>
	<keyword>Children</keyword>
</DOC>